Montreux, Switzerland | April 4, 2023 – MedXCell SA, a European venture builder that specializes in cell therapy for major diseases such as cancer, autoimmune,
Montreux, Switzerland | November 2, 2022 – CYTEA|BIO, a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies combining non genetically modified effector cells (such as
Montreux, Switzerland | March 11, 2022 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and
Montreux, Switzerland | August 26, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and accessible
Montreux, Switzerland | June 4, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and
Montreux, Switzerland | May 17, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and
This website contains information about products that may not be available in all countries, available under different trademarks or for different indications. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development and described on this site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider
© All rights reserved 2022 – MedXCell SA
